Traders should monitor upcoming regulatory feedback and initiation of the PSP Phase 1b trial as near-term catalysts. Positive momentum in ARV-102 could re-rate the stock, especially given lack of current treatments targeting LRRK2 or lysosomal dysfunction in PSP.
ARVN drugs
ARVN drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 18 $10.89entry
- T+1 · 8mo ago +2.57%α +2.84% · $11.17
- T+5 · 8mo ago +0.28%α +0.99% · $10.92
- T+20 · 7mo ago +1.01%α −5.04% · $11.00
- T+60 · 5mo ago −34.89%α −46.42% · $7.09
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Arvinas presented positive Phase 1 data for ARV-102, showing approximately 50% or greater reduction of LRRK2 in cerebrospinal fluid in Parkinson’s patients, with good tolerability and biomarker improvements. The company plans to initiate a Phase 1b trial in progressive supranuclear palsy (PSP) in Q2 2026, pending regulatory feedback, supporting further development in neurodegenerative diseases.
Key Facts
- ARV-102 achieved ≥50% LRRK2 reduction in CSF by day 14 and sustained through day 28 across all dose levels (20–80 mg) in Parkinson’s patients
- ARV-102 demonstrated dose-dependent brain penetration and reduction of endolysosomal and neuroinflammatory biomarkers (e.g., CD68, GPNMB)
- No serious adverse events (SAEs) were reported; drug was well tolerated over 28 days
- Arvinas plans to initiate a Phase 1b trial in PSP in Q2 2026, with potential registrational trial by late 2026
- Data presented at AD/PD™ 2026 conference, adding scientific credibility
Financial Impact
No direct financial impact yet; clinical advancement increases probability of success and future revenue potential in high-unmet-need neurodegenerative markets
Risk Factors
- Phase 1 biomarker data does not guarantee clinical efficacy in later trials
- Regulatory delays could push back Phase 1b initiation in PSP
- Competitive landscape may evolve with other LRRK2 inhibitors or tau-targeted therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258013 |
Track record
21 reports on ARVN
5 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +28.62% at T+60 after the Feb 23, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 3, 202613d ago S-3 Bearish 5/10 Entry $7.42 to $6.55 Now $6.77 +8.76% ▲ +11.73% +7.32% vs SPY
- Nov 3, 202613d ago 8-K Bearish 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 4/10 Entry $7.09 to $7.42 Now $6.77 −4.51% ▲ +4.65% +3.00% vs SPY
- Sep 4, 202610w ago 144 Neutral 3/10 Entry $9.08 to $8.76 Now $6.77 −25.44% ▼ −3.52% −3.06% vs SPY
- Jun 22, 202621w ago 8-K Neutral 3/10 Entry $8.14 to $8.05 Now $6.77 −16.83% ▼ −1.11% −1.06% vs SPY
- Jun 2, 202623w ago 8-K Bearish 6/10 Entry $7.70 to $7.74 Now $6.77 +12.08% ▼ −0.52% −0.12% vs SPY
- May 12, 202626w ago 8-K Mixed 6/10 No price data
- May 12, 202626w ago 8-K Bullish 7/10 Entry $9.57 to $9.87 Now $6.77 −29.26% ▲ +3.13% +2.56% vs SPY
- May 12, 202626w ago Press Release Bearish 8/10 Entry $9.57 to $9.87 Now $6.77 +29.26% ▼ −3.13% −2.56% vs SPY
- May 8, 202627w ago 144 Neutral 2/10 Entry $9.66 to $9.57 Now $6.77 −29.92% ▼ −0.93% −0.80% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers